33 min listen
Should We Be Concerned About Viral Rebound With Antiviral Agents?
Should We Be Concerned About Viral Rebound With Antiviral Agents?
ratings:
Length:
5 minutes
Released:
Dec 30, 2022
Format:
Podcast episode
Description
Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 rebound, including:Prevalence of COVID-19 reboundCOVID-19 rebound and antiviral useManagement of COVID-19 rebound Presenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite Director COVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious Diseases PharmacyGrady Health SystemAtlanta, GeorgiaLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL
Released:
Dec 30, 2022
Format:
Podcast episode
Titles in the series (100)
COVID-19: Answering the Questions, Part 5: In Part 5 of this ongoing 12-part COVID-19 series, listen to a brief update on the epidemiology of SARS-CoV-2 and evidence-based interventions for reducing transmission, followed by answers to critical clinician questions on COVID-19 transmission and mitigation by David Heymann, BA, MD, DTM&H. by CCO Infectious Disease Podcast